Inotrem

📍 Paris, France🗓 Founded 2013👥 33 employees💰 Last funded Dec 2019
Biotechnology Research🌐 inotrem.com
Website LinkedIn
Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock. Founded in 2013, with offices in Paris and a technology center in Nancy (France), the company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Leveraging its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with applications in a number of therapeutic indications such as septic shock or myocardial infarction. Next to acute inflammatory syndromes, Inotrem is also developing a program targeting chronic inflammatory diseases.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2013
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Inotrem?
Inotrem has 1 investors on record on gritt.io and 1 late-stage investors.
When did Inotrem last raise funding?
The most recent investment in Inotrem recorded on gritt.io was in December 2019.
When was Inotrem founded?
Inotrem was founded in 2013.
What industry is Inotrem in?
Inotrem operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Inotrem based?
Inotrem is headquartered in Paris, France.